Department of General Surgery, Guizhou Provincial People's Hospital, Guiyang City, Guizhou Province, China.
Department of Urology, Guizhou Provincial People's Hospital, Guiyang City, Guizhou Province, China.
Endocr J. 2021 Jun 28;68(6):713-727. doi: 10.1507/endocrj.EJ20-0726. Epub 2021 Mar 13.
The circular RNA PRKCI (circ-PRKCI; ID: hsa_circ_0122683) is highly expressed in human papillary thyroid cancer (PTC) tumors according to GSE93522 dataset. However, its role in PTC tumorigenesis remains to be documented. Here, quantitative real-time PCR showed that expression of circ-PRKCI was abnormally upregulated in human PTC patients' tumors and cells, and higher circ-PRKCI might predict lymph node metastasis and recurrence. Functionally, cell behaviors were measured by 3-(4,5-dimethylthiazolyl-2)-2,5-diphenyltetrazolium bromide assay, colony formation assay, fluorescence-activated cell sorting method, scratch wound assay, transwell assay, western blotting, and assay kits for glucose and lactate. As a result, circ-PRKCI knockdown could suppress cell cycle progression of PTC cells and restrain the abilities of cell proliferation, colony formation, wound closure, invasion, glucose consumption and lactate production, accompanied with decreased levels of matrix metalloproteinase-2 (MMP2), MMP9 and Snail. Moreover, above-mentioned inhibition could be imitated by overexpressing microRNA-335-5p (miR-335). Molecularly, circ-PRKCI functioned as a sponge for miR-335 and miR-335 could further targeted E2F transcription factor-3 (E2F3), according to dual-luciferase reporter assay and RNA immunoprecipitation. However, downregulating miR-335 diminished the effects of circ-PRKCI role on cell growth, metastasis and glycolysis in PTC cells; besides, there was a counteractive effect between miR-335 upregulation and E2F3 upregulation in PTC cells as well. Furthermore, xenograft experiment revealed that silencing circ-PRKCI could retard tumor growth of PTC cells in vivo. Collectively, circ-PRKCI exerted oncogenic role in PTC by antagonizing cell progression and glycolysis via regulating miR-335/E2F3 axis, suggesting circ-PRKCI was a potential biomarker and target for PTC.
环状 RNA PRKCI(circ-PRKCI;ID:hsa_circ_0122683)根据 GSE93522 数据集在人甲状腺乳头状癌(PTC)肿瘤中高度表达。然而,其在 PTC 肿瘤发生中的作用仍有待证实。这里,实时定量 PCR 显示,circ-PRKCI 在人 PTC 患者的肿瘤和细胞中异常上调表达,并且较高的 circ-PRKCI 可能预测淋巴结转移和复发。功能上,通过 3-(4,5-二甲基噻唑基-2)-2,5-二苯基四氮唑溴盐测定法、集落形成测定法、荧光激活细胞分选法、划痕愈合测定法、Transwell 测定法、Western blot 测定法和葡萄糖和乳酸测定试剂盒来测量细胞行为。结果表明,circ-PRKCI 敲低可抑制 PTC 细胞的细胞周期进程,并抑制细胞增殖、集落形成、伤口闭合、侵袭、葡萄糖消耗和乳酸生成的能力,同时降低基质金属蛋白酶-2(MMP2)、MMP9 和 Snail 的水平。此外,上述抑制作用可以通过过表达 microRNA-335-5p(miR-335)来模拟。分子上,circ-PRKCI 作为 miR-335 的海绵,miR-335 可以进一步靶向 E2F 转录因子-3(E2F3),根据双荧光素酶报告基因测定和 RNA 免疫沉淀。然而,下调 miR-335 减弱了 circ-PRKCI 在 PTC 细胞中对细胞生长、转移和糖酵解的作用;此外,在 PTC 细胞中,miR-335 的上调和 E2F3 的上调之间存在拮抗作用。此外,异种移植实验表明,沉默 circ-PRKCI 可在体内抑制 PTC 细胞的肿瘤生长。总之,circ-PRKCI 通过调节 miR-335/E2F3 轴拮抗细胞进展和糖酵解,在 PTC 中发挥致癌作用,提示 circ-PRKCI 可能是 PTC 的潜在生物标志物和靶点。